Logo image
In vivo acceleration of heart relaxation performance by parvalbumin gene delivery
Journal article   Open access   Peer reviewed

In vivo acceleration of heart relaxation performance by parvalbumin gene delivery

Michael L. Szatkowski, Margaret V. Westfall, Carlen A. Gomez, Philip A. Wahr, Daniel E. Michele, Christiana DelloRusso, Immanuel I. Turner, Katie E. Hong, Faris P. Albayya and Joseph M. Metzger
The Journal of clinical investigation, v 107(2), 191
01 Jan 2001
PMID: 11160135
url
https://doi.org/10.1172/JCI9862View
Published, Version of Record (VoR) Open

Abstract

Defective cardiac muscle relaxation plays a causal role in heart failure. Shown here is the new in vivo application of parvalbumin, a calcium-binding protein that facilitates ultrafast relaxation of specialized skeletal muscles. Parvalbumin is not naturally expressed in the heart. We show that parvalbumin gene transfer to the heart in vivo produces levels of parvalbumin characteristic of fast skeletal muscles, causes a physiologically relevant acceleration of heart relaxation performance in normal hearts, and enhances relaxation performance in an animal model of slowed cardiac muscle relaxation. Parvalbumin may offer the unique potential to correct defective relaxation in energetically compromised failing hearts because the relaxation-enhancement effect of parvalbumin arises from an ATP-independent mechanism. Additionally, parvalbumin gene transfer may provide a new therapeutic approach to correct cellular disturbances in calcium signaling pathways that cause abnormal growth or damage in the heart or other organs.

Metrics

14 Record Views
65 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Medicine, Research & Experimental
Logo image